• Industry
  • Finance
  • Culture
  • Politics
  • Science
  • Wellness
  • Industry
  • Finance
  • Culture
  • Politics
  • Science
  • Wellness
AbbVie Withdraws Patent Challenge, Clearing Path for Enveric’s Psychedelic IP Strategy
Breaking: Enveric Reports New Mechanistic Data Supporting Non-Hallucinogenic Neuroplastogen Strategy
Two New Studies Are Rewriting the Rules of Psychedelic Drug Development
Starting 2026: Why Neuroplastogens Are Quietly Redefining the Psychedelic Medicine Narrative
Psychedelics in 2025: A Year of Proof, Pullback, and a Clearer Path Forward
Delix Therapeutics Reports Strong Phase Ib Results
Childhood Trauma’s Role in Men’s Substance Use Disorders
Human-Centered AI in Healthcare
Enveric Biosciences Doubles Down on IP Strength as Psychedelic Biotech Sector Heats Up
The IP Battle Behind the $1.2B Psychedelic Acquisition—and Why Enveric Biosciences Is a Name to Watch
Shop

Psychedelics in Dubai: Therapeutic Role of Psychedelics Explored at Conference in the Arab Region

Microdose NewsDesk by Microdose NewsDesk
June 7, 2023
in Industry
Reading Time: 3 mins read
A A
Psychedelics in Dubai: Therapeutic Role of Psychedelics Explored at Conference in the Arab Region

 

Therapeutic Role of Psychedelics Explored at Conference in the Arab Region

 

As the Arabian Peninsula works to lead cutting-edge sectors, once taboo treatments are beginning to be considered, discussed, and researched

DUBAI, Arab Emirates, June 5, 2023 – The Energia Foundation is thrilled to announce a milestone in psychedelic therapeutics education in the Arab region, as part of the ‘Dialogues in MentalHealth: Novel Treatments in Mood Disorders’ conference held in partnership with Tabula Rasa Ventures, Reem Neuroscience center, Abu Dhabi and The Valens Clinic Dubai. This academic event, set to take place on June 10th in Dubai, UAE, will explore the latest advances in mental health disorders including Neuromodulation, Esketamine, redirection of medication and marks the first-ever conference with dedicated programming exploring the global advancement in the field of psychedelic-assisted therapies.

Novel Treatments in Mood Disorders aims to catalyze a new era of education, research collaboration, and professional development in mental health and the treatment of mood disorders. With a growing global recognition of the therapeutic potential of psychedelic-assisted therapies, this conference will play a pivotal role in bringing this cutting-edge modality to the forefront of health systems in the region. A distinguished lineup of international experts, renowned researchers, clinicians, and thought leaders in the field of psychedelic-assisted therapies will be presenting their latest work, including: Rachel Yehuda, Director of the Mt. Sinai Center for Psychedelic Psychotherapy and Trauma Research, Jesse Gould, Founder of the Heroic Hearts Project, and Maria Velkova, Managing Partner of Tabula Rasa Ventures.

[bsa_pro_ad_space id=2]
ADVERTISEMENT

“We are excited to pioneer education around the potential for psychedelic therapeutics in the MENA region,” said Marik Hazan, Executive Director at the Energia Foundation. “This conference will foster dialogue, collaboration, and education among professionals, researchers, and stakeholders, while promoting a medicalized, therapeutic, and evidence-based approach to psychedelic-assisted therapies.”

Continue on your trip...

Two New Studies Are Rewriting the Rules of Psychedelic Drug Development

Starting 2026: Why Neuroplastogens Are Quietly Redefining the Psychedelic Medicine Narrative

Psychedelics in 2025: A Year of Proof, Pullback, and a Clearer Path Forward

Novel Treatments in Mood Disorders

Purchase Lasix Today

will provide a platform for attendees to explore a wide range of topics related to psychedelic therapeutics, including the potential applications in mental health treatments, substance abuse disorders, palliative care, and post-traumatic stress disorder (PTSD).

Through in-depth discussions and workshops, participants will gain a deeper understanding of the therapeutic mechanisms, best practices, and regulatory frameworks associated with psychedelic-assisted treatments.

“We started the Dialogues in Mental Health Series with Dr Samer Makhoul a year ago and are thrilled to see its growing impact amongst the mental health community in the GCC,” added Joseph El Khoury, Founder of the Valens Clinic, Dubai. “Therapists in the region are staying updated on the latest scientific evidence and clinical trials, desperately looking for ways to help move the needle on patient outcomes in mental health. Practitioners are aware of the developments, particularly in the US, but are keen on in-person networking, training, education, and collaboration to sharpen their understanding of these innovative therapies. This conference is a keystep to bring the region up to speed with progress on the international scene with the ultimate aim to reduce the burden of mental health ailments in the region.”

Novel Treatments in Mood Disorders welcomes professionals, researchers, therapists, policymakers, and individuals interested in the field of psychedelic-assisted therapies to join this landmark event. Request for invitation and further details about the conference can be found on the official conference website: energiafoundation.org/mena.

 

Source: Energia Foundation Incorporated

About Energia Foundation Incorporated

[bsa_pro_ad_space id=2]
ADVERTISEMENT

Through powerful events, experiences, and demonstrations, the Energia Foundation lays the groundwork for establishing institutions that fight for long lasting change.

http://energiafoundation.org

Original Source: www.newswire.com

Microdose NewsDesk

Microdose NewsDesk

Microdose's editorial department brings you the latest news and industry insights.

Next Post
Psychedelic Reform and Decrim Update

The Difference Between Psychedelic Legalization and Decriminalization

Who do you think will be first to successfully develop a psychedelic drug?
This field is for validation purposes and should be left unchanged.

Latest News

AbbVie Withdraws Patent Challenge, Clearing Path for Enveric’s Psychedelic IP Strategy

Breaking: Enveric Reports New Mechanistic Data Supporting Non-Hallucinogenic Neuroplastogen Strategy

Two New Studies Are Rewriting the Rules of Psychedelic Drug Development

ADVERTISEMENT

Follow us on social

Microdose is your guide to psychedelics. Our mission is to shift the world’s perception of psychedelic medicine.

Read the News
  • Industry
  • Culture
  • Science
  • Finance
  • Law & Politics
  • Health & Wellness
  • Industry
  • Culture
  • Science
  • Finance
  • Law & Politics
  • Health & Wellness
Online Courses
  • Microdosing
  • MDMA
  • Ketamine
  • Psychedelic Counseling
  • Addiction Treatment
  • Classic Psychedelics
  • Microdosing
  • MDMA
  • Ketamine
  • Psychedelic Counseling
  • Addiction Treatment
  • Classic Psychedelics
Subscribe for Exclusive Updates

Terms & Conditions / Privacy Policy

© 2026 MD Media Inc. All rights reserved. The information provided on this website does not, and is not intended to, constitute financial, legal or medical advice. All information, content, and materials available on this site are for general educational and informational purposes only.

WordPress Ads
No Result
View All Result
  • Landing Page
  • Buy JNews
  • Support Forum
  • Contact Us

© 2026 JNews - Premium WordPress news & magazine theme by Jegtheme.